This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Radius Health Announces Positive Data on Lead Drug Tymlos
by Zacks Equity Research
Radius Health (RDUS) announces positive results from the extended study, ACTIVExtend on its drug Tymlos whcih is approved for the treatment of postmenopausal women with high risk osteoporosis for fracture.
Is Eli Lilly and Company (LLY) Stock a Good Value Pick Now?
by Zacks Equity Research
Let's see if Eli Lilly and Company (LLY) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
AVEO Pharmaceuticals (AVEO) Q4 Loss Widens, Shares Down
by Zacks Equity Research
AVEO Pharmaceuticals (AVEO) reports wider-than-expected loss in the fourth quarter with revenues missing estimates. The top line also declines year over year.
Merck's Keytruda Gets Priority Review for Cervical Cancer
by Zacks Equity Research
Merck's (MRK) sBLA for Keytruda to expand its label for the treatment of advanced cervical cancer gets acceptance for priority review by the FDA.
The Zacks Analyst Blog Highlights: Coca-Cola, Eli Lilly, Occidental Petroleum, Ross Stores and Wynn Resorts
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Coca-Cola, Eli Lilly, Occidental Petroleum, Ross Stores and Wynn Resorts
Celldex (CLDX) Q4 Loss Narrows, Revenues Beat, Shares Up
by Zacks Equity Research
Celldex (CLDX) reports narrower-than-expected loss in Q4 with sales also beating estimates. Moreover, shares rise in after-hours trading on Mar 7 following the results.
Merck to Pay $300M Upfront to Co-Develop Eisai's Cancer Drug
by Zacks Equity Research
Merck (MRK) is going to pay $300 million upfront to Japan's Eisai to jointly develop and commercialize the latter's pipeline candidate Lenvima.
Lilly, Boehringer to Expand Jardiance Heart Failure Program
by Zacks Equity Research
Lilly (LLY) and Boehringer plan to expand their clinical trial program for Jardiance in chronic heart failure through clinical trials.
Are Alzheimer's-Focused Stocks Set for a Financial Windfall?
by Zacks Equity Research
Launch of the blood tests will help companies focused on developing preventive treatments make billions.
Radius (RDUS) Q4 Loss Wider Than Expected on Higher Expenses
by Zacks Equity Research
Radius Health (RDUS) reported a wider-than-expected loss in the fourth quarter due to higher operating expenses related to the commercialization of Tymlos.
Why Is Eli Lilly (LLY) Down 7.2% Since its Last Earnings Report?
by Zacks Equity Research
Eli Lilly (LLY) reported earnings 30 days ago. What's next for the company? We take a look at earnings estimates for some clues.
Lilly's Verzenio Wins FDA Nod for First Line Breast Cancer
by Zacks Equity Research
Lilly's (LLY) new advanced breast cancer treatment Verzenio (abemaciclib) gains FDA approval in first-line setting.
Radius Health (RDUS) to Disappoint Investors in Q4 Earnings?
by Zacks Equity Research
Investors are expected to focus on the uptake of the lead drug, Tymlos when Radius Health (RDUS) reports its fourth-quarter results.
United Therapeutics (UTHR) Q4 Earnings Decline on High Costs
by Zacks Equity Research
United Therapeutics' (UTHR) earnings per share decline in Q4 due to higher operating costs. Shares sink almost 10%.
FDA Sets the Stage for Earlier-Stage Alzheimer's Treatments
by Zacks Equity Research
FDA's proposed guidelines come in a week when major disappointments in the field were announced by companies developing drugs to treat Alzheimer's.
Lilly's Taltz Positive in Phase III Label Expansion Study
by Zacks Equity Research
Lilly's (LLY) psoriasis drug, Taltz, meets all endpoints in a phase III study evaluating it in patients with ankylosing spondylitis.
Merck (MRK) Halts Another Late Stage Study on Alzheimer's
by Zacks Equity Research
Merck (MRK) stalls a phase III study evaluating verubecestat for the treatment of prodromal Alzheimer's disease on the recommendation of an external data monitoring committee.
Pfizer Announces FDA Acceptance of NDA for NSCLC Candidate
by Zacks Equity Research
Pfizer's (PFE) regulatory applications seeking approval for tyrosine kinase inhibitor, lorlatininb, for treating second or later line NSCLC accepted in the United States, Europe and Japan.
Can Jakafi Performance Drive Incyte's (INCY) Q4 Earnings?
by Zacks Equity Research
Growth in Jakafi sales are likely to help Incyte (INCY) to beat on earnings in Q4.
Solid Q4 Earnings Drive Pharma ETF Outlook
by Sweta Killa
Although pharma ETFs saw terrible trading over the past one month in the latest global market rout, the string of earnings beat bolstered confidence in the space.
Array's Melanoma Combo Shows Positive Overall Survival Data
by Zacks Equity Research
Array's (ARRY) shares gain on impressive overall survival data from a phase III trial of combined binimetinib and encorafenib for BRAF-mutant advanced, unresectable or metastatic melanoma.
Bristol-Myers' Opdivo/Yervoy Combo Positive in Cancer Study
by Zacks Equity Research
Bristol-Myers' (BMY) blockbuster drug, Opdivo, in combination with Yervoy, proves its worth again by demonstrating superiority in a lung cancer study.
ADP, Q4, SOTU Boost Market
by Zacks Equity Research
ADP, Q4, SOTU Boost Market
Markets Rebound Bigly on ADP, Q4, SOTU
by Mark Vickery
After two days of market sell-off, suddenly everything's coming up roses again.
Lilly (LLY) Beats on Q4 Earnings, Raises 2018 EPS Guidance
by Zacks Equity Research
Lilly (LLY) beats on earnings and sales in Q4 and raises EPS outlook for 2018, reflecting a positive impact of the U.S. tax reform.